Baxter InternationalMEX:BAX 44 Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus rates MEX:BAX with a GF Score™ of 44/100 and a GF Value™ of MXN623.50 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Baxter International ranks worse than 131925.99% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Baxter International's annualized net income for the quarter that ended in Mar. 2026 was MXN-1,082 Mil. Baxter International's average shareholder tangible equity for the quarter that ended in Mar. 2026 was MXN-56,246 Mil. Therefore, Baxter International's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was N/A%.
The historical rank and industry rank for Baxter International's Return-on-Tangible-Equity or its related term are showing as below:
During the past 13 years, Baxter International's highest Return-on-Tangible-Equity was 105.71%. The lowest was 0.00%. And the median was 30.69%.
MEX:BAX's Return-on-Tangible-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 4.08 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Baxter International (MEX:BAX) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Baxter International Return-on-Tangible-Equity Related Terms
Baxter International Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Baxter International's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baxter International Return-on-Tangible-Equity Chart
MEX:BAX vs ALGN, SOLV, COO: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Baxter International's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Baxter International Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Baxter International's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Baxter International's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Baxter International (MEX:BAX) has a Return-on-Tangible-Equity of 0.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Baxter International and its competitors. According to the industry distribution chart, Baxter International ranks #999999 out of 758 companies in the Medical Devices & Instruments industry.
Is Baxter International's Return-on-Tangible-Equity too high?
Baxter International's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Baxter International ranks #999999 out of 758 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Baxter International has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Baxter International's Return-on-Tangible-Equity compare to ALGN and SOLV?
According to the Medical Devices & Instruments industry distribution chart, Baxter International ranks #999999 out of 758 companies for Return-on-Tangible-Equity. This places Baxter International in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Baxter International and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Baxter International's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baxter International stock overvalued right now?
Based on GuruFocus' analysis, Baxter International (MEX:BAX) is currently considered Possible Value Trap. The stock's GF Value™ is MXN623.50, compared to a current price of MXN368.00 — trading 41% below its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Baxter International's overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Baxter International (MEX:BAX), the current Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Baxter International (MEX:BAX) Overvalued in 2026?
Based on GuruFocus' analysis, Baxter International stock appears to be undervalued.
The current stock price of MXN368.00 is trading 41% below its estimated GF Value™ of MXN623.50.
GuruFocus considers Baxter International to be Possible Value Trap.
Key valuation signals for MEX:BAX:
Return-on-Tangible-Equity: 0.00%
GF Value™: MXN623.50 vs. price of MXN368.00 (41% below fair value)
No single metric tells the full story. See the MEX:BAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
44GF Score
Get the complete analysis for MEX:BAX
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BAX has been successfully added to your 
